The FDA has approved Dupixent for the treatment of children aged two to 11 years with chronic spontaneous urticaria who remain symptomatic despite histamine-1 antihistamine treatment. This expands the previous approval for Dupixent in adults and adolescents aged 12 years and older. The approval is based primarily on data from the LIBERTY-CUPID clinical study program.
Dupilumab is being jointly developed by Sanofi (SNY,SAN.PA) and Regeneron (REGN) under a global collaboration agreement. Dupixent is now approved for nine different allergy-related conditions, from asthma to atopic dermatitis. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in phase 3 studies.
At last close, shares of Sanofi were trading at 80.78 euros, down 0.30%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.